Erudio Healtherudio.com
Drug
Lorlatinib trials: what clinicians said in public
No HCP commentary report on a trial studying lorlatinib yet. Erudio has found public clinician commentary on 5 clinical trials studying lorlatinib, including CROWN, LORIN, NCI-NRG ALK Protocol and NCT03612154. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LORIN NCT05740943 · Guangdong Provincial People's Hospital DeepView → | ALK fusion stage III non-small cell lung cancer | Phase 2 | Deep | View | |||
| CROWN NCT03052608 · Pfizer DeepView → | Not given | Phase 3 | Deep | View | |||
| NCI-NRG ALK Protocol NCT03737994 · National Cancer Institute (NCI) FocusedView → | previously treated ALK-positive stage IV non-squamous NSCLC | Phase 2 | Focused | View | |||
| NCT03612154 NCT03612154 · National Cancer Center, Korea FocusedView → | advanced ROS1-positive non-small cell lung cancer | Phase 2 | Focused | View | |||
| NCT04292119 NCT04292119 · Massachusetts General Hospital FocusedView → | anaplastic lymphoma kinase-rearranged lung cancer | Phase 1/Phase 2 | Focused | View | |||